DOCSLIB.ORG

Volume 27 • Number 1 • 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Volume 27 • Number 1 • 2010 Newsletter A publication of the Controlled Release Society Volume 27 • Number 1 • 2010 What’s Inside New C&DP Representative Joins Newsletter Board Portland Awaits Phase Separation Behavior of Fusidic Acid in Microspheres Tailoring In Vitro Cell Responses of Porous Silicon Nanoencapsulation Using Microfluidizer® Processors Gamma Scintigraphy and Canine Respiratory Models News from the CRS Focus Groups CRS-AAPS Workshop a Success C&DP Patent Watch IT’S ALL ABOUT THE CONTENT That’s why subscribers of Drug Delivery Technology spend 40 minutes reading each issue. Drug Delivery Technology is the only publication completely dedicated to product development. Highlight your message to our 20,000 subscribers through print and online marketing opportunities! Y 10 printed issues Y eNewsletter sent twice per month, featuring the latest news CONTACT US TODAY shaping the industry (lim ited to 5 sponsors per month) EAST & MIDWEST Victoria Geis • Tel: (703) 212- 7735 • [email protected] Y Website Banner Advertising WEST Y Webinars and webcasts Warren DeGraff • Tel: (415) 721-0664 • [email protected] INTERNATIONAL Y Listings in the Resource Directory Ralph Vitaro • Tel: (973) 263-5476 • [email protected] (All listings in print and the digital WEBINARS version posted online) Michael J. Masters • 973-299-1200 • [email protected] Newsletter Steven Giannos Vol. 27 • No. 1 • 2010 Editor Table of Contents From the Editor .................................................................................................................. 2 From the President ............................................................................................................ 3 Editorial Board Bozena Michniak-Kohn Starting Thoughts from the C&DP Representative to the CRS Newsletter Editor Editorial Board ..................................................................................................................... 4 37th CRS Annual Meeting & Exposition ......................................................................... 6 Scientifically Speaking Phase Separation Behavior of Fusidic Acid in Microspheres Influences Morphology and Drug Release ........................................................................................... 8 Tailoring In Vitro Cell Responses of Porous Silicon Micro- and Nanoparticles .................. 10 Yvonne Perrie Spotlight Editor Nanoencapsulation Using Microfluidizer® Processors Via “Top Down” and “Bottom Up” Processing Methods .................................................................................... 12 Gamma Scintigraphy: A Useful Tool in Canine Respiratory Models .................................. 14 From the Vet Group A New Title in Veterinary Drug Delivery ............................................................................ 16 Chapter News Rod Walker UKICRS Symposium 2010 .................................................................................................. 18 Editor CRS Illinois Student Chapter Holds ‘80s Game Night ....................................................... 18 Joint Meeting of PAT2009 and the CRS Israeli Chapter .................................................... 19 Welcome CRS Student Chapter The Hebrew University of Jerusalem .............................. 20 CRS Italian Chapter ........................................................................................................... 20 CRS New Zealand and Australian Chapters Hold Workshop on “Improving the Bioavailability of Poorly Water-Soluble Drugs” ........................................ 21 Satellite Workshops Arlene McDowell CRS-AAPS Satellite Workshop a Resounding Success ...................................................... 23 Editorial Board CRS Focus Groups News from the CRS Nanomedicine Focus Group ............................................................. 25 CRS Oral Drug Delivery Focus Group Update .................................................................. 27 Patent Watch ................................................................................................................... 28 In the News ..................................................................................................................... 33 Event Calendar ........................................................................................................ Cover 4 Charles Frey Editorial Board Advertisers’ Index Drug Delivery Technology ...................................................................................... Cover 2 Elsevier ............................................................................................................................... 5 SMi .................................................................................................................................... 32 1 From the Editor Editors Arlene McDowell Steven Giannos Bozena Michniak-Kohn New Zealand’s National School of Yvonne Perrie Pharmacy, Univerity of Otago Rod Walker Dunedin, New Zealand Editorial Board Arlene McDowell (Vet Group) Charles Frey (C&DP) Publications Committee Chair elcome to the first issue of the CRS Newsletter for the new decade. We wish Ijeoma Uchegbu you a very happy new year! And, to represent the international nature of our Society—W gung hay fat choy, jour des étrennes, gutes nue Jahr, say hay boke-mahn he pah The CRS Newsletter is the official newslet- du say oh, and godt nytår. I have fond memories of my family and the new year ter of the Controlled Release Society. The newsletter is published five times annually tradition of “first-footing.” This is a European tradition, where to bring good luck a providing scientific and technical informa- male with dark hair must be the first person to enter the house, preferably with a tion pertinent to the controlled release piece of coal, saying, “Lang may your lum reek” (“Long may your chimney smoke”). community and news about society and My father had dark hair, and so he was a popular visitor on new year’s day. There are chapter activities. Members can receive the newsletter via mail. The newsletter many lovely traditions around the world surrounding the new year, and a great CRS may also be viewed online at tradition is the annual meeting. Our CRS Annual Meeting & Exposition in 2010 www.controlledreleasesociety.org. will be held in Portland, OR—“The city of roses.” This will help some of you solve Newsletter articles reflect only the views the little mystery of why all those people had red roses on their name badges at the of the authors. Publication of articles or 2009 CRS Annual Meeting. The meeting organising committee thanks those who advertisements within the CRS Newsletter have agreed to be abstract reviewers for the CRS Annual Meeting in Portland. does not constitute endorsement by the Controlled Release Society or its agents Abstract reviewing is a very important part of the meeting, and we appreciate the of products, services, or views expressed time and effort that goes into ensuring that the high standard of podium and poster herein. No representation is made as to presentations is maintained. the accuracy hereof and the publication is printed subject to errors and omissions. The CRS Newsletter continues to grow and provide increased communication with Editorial contributions should be directed to the CRS Newsletter Editors, our members. With six issues planned for 2010, there is lots of great reading to come. ([email protected]) and are As always, we welcome your contributions. Please contact a member of the CRS subject to the terms and conditions of Newsletter Editorial Board if you would like to submit an article or have any the Editorial and Publication Release. suggestions about the Newsletter. We are also giving members the opportunity to Publisher assumes no responsibility for the safety or return of artwork, photographs, promote images of their controlled release science on the cover of the CRS or manuscripts. Newsletter. If you have a great image you would like to share, we would love to see it. Requests for advertisement placement may Send electronic copies through the online dropbox at http://dropbox.yousendit.com/ be directed to Debby Woodard, Business scisoc (see page 15 in this issue for more details). Development Department; telephone +1.651.994.3817, or e-mail at dwoodard@ In this issue you can read about the activities of a number of CRS Chapters scisoc.org. All advertisements are subject to “General Conditions of Sale.” worldwide, including a new Student Chapter at The Hebrew University of Jerusalem and be at the right place at the right time for the UKI CRS symposium in April, Unauthorized reproduction in whole or in part is prohibited. Requests for permission where you will find out about controlled release in drug delivery. I encourage you to should be directed to the Editors at seek out a Chapter located near you and get involved. Plus check out our regular [email protected]. forums, including Scientifically Speaking, Patent Watch, From the Vet Group, and In ©Copyright 2010 Controlled Release the News. Society. All rights reserved. Controlled Release Society On behalf of the editorial team of the CRS Newsletter, I wish you a happy, healthy, 3340 Pilot Knob Road and successful 2010. St. Paul, MN 55121 U.S.A. Telephone: +1.651.454.7250 Best wishes, Facsimile: +1.651.454.0766 n Visit www.controlledreleasesociety.org or Arlene McDowell e-mail [email protected] on questions about membership, meetings, publications, and services. Contact [email protected] for
Load more

Recommended publications
  • Treating Herpes Zoster and Postherpetic Neuralgia
    ® VOVOLL XX I XXIII• NO 1• NO• JU 4N E• MAY2013 2015 Treating Herpes Zoster and Postherpetic Neuralgia Vol.ÊXXI,ÊIssueÊ1Ê JuneÊ2013 Editorialostherpetic Board neuralgia (PHN) but a minority of patients experience months and 15% had pain at 2 years in is the most frequent chronic pain (PHN) persisting for months, years, a Dutch study.6 In the landmark zoster Editor-in-Chief PsychosocialÊAspectsÊofÊChronicÊPelvicÊPain complication of herpes zoster or even a lifetime. vaccine study, which included almost JaneÊC.ÊBallantyne,ÊMD,ÊFRCA (shingles).1 Herpes zoster (HZ) Anesthesiology,ÊPainÊMedicine 40,000 people aged 60 years or older PUSA represents a reactivation of the vari- Epidemiology of HZ and PHN (of whom fewer than 1000 developed cella zoster virus (VZV), a ubiquitous, Pain is unwanted, is unfortunately common, and remains essential for survival (i.e., AdvisoryÊBoard HZ) and where PHN was defined as highly neurotropic, exclusively human Accordingevading toda ang recenter) and systematic facilitating medical diagnoses. This complex amalgamation of MichaelÊJ.ÊCousins,ÊMD,ÊDSC pain intensity of 3/10 or more, 30% of -herpesvirus. Primary infection causes review,sensati theon, incidence emotions, of a ndHZ t houghis 3–5 ts manifests itself as pain behavior. Pain is a moti- α PainÊMedicine,ÊPalliativeÊMedicine 1patients who developed HZ had PHN - Australia casesvati perng f1000actor person-years.for physician 3c Theonsu ltations and for emergency department visits and is varicella (chickenpox), after which VZV at 1 month, 12% at 3 months, and 5% age-specific incidence rates of HZ were becomes latent in sensory ganglia along at 6 months in the placebo group.7 Ac- similar across countries, with a steep the entire neuraxis.
    [Show full text]
  • CLINICAL TRIALS Safety and Immunogenicity of a Nicotine Conjugate Vaccine in Current Smokers
    CLINICAL TRIALS Safety and immunogenicity of a nicotine conjugate vaccine in current smokers Immunotherapy is a novel potential treatment for nicotine addiction. The aim of this study was to assess the safety and immunogenicity of a nicotine conjugate vaccine, NicVAX, and its effects on smoking behavior. were recruited for a noncessation treatment study and assigned to 1 of 3 doses of the (68 ؍ Smokers (N nicotine vaccine (50, 100, or 200 ␮g) or placebo. They were injected on days 0, 28, 56, and 182 and monitored for a period of 38 weeks. Results showed that the nicotine vaccine was safe and well tolerated. Vaccine immunogenicity was dose-related (P < .001), with the highest dose eliciting antibody concentrations within the anticipated range of efficacy. There was no evidence of compensatory smoking or precipitation of nicotine withdrawal with the nicotine vaccine. The 30-day abstinence rate was significantly different across with the highest rate of abstinence occurring with 200 ␮g. The nicotine vaccine appears ,(02. ؍ the 4 doses (P to be a promising medication for tobacco dependence. (Clin Pharmacol Ther 2005;78:456-67.) Dorothy K. Hatsukami, PhD, Stephen Rennard, MD, Douglas Jorenby, PhD, Michael Fiore, MD, MPH, Joseph Koopmeiners, Arjen de Vos, MD, PhD, Gary Horwith, MD, and Paul R. Pentel, MD Minneapolis, Minn, Omaha, Neb, Madison, Wis, and Rockville, Md Surveys show that, although about 41% of smokers apy, is about 25% on average.2 Moreover, these per- make a quit attempt each year, less than 5% of smokers centages most likely exaggerate the efficacy of are successful at remaining abstinent for 3 months to a intervention because these trials are typically composed year.1 Smokers seeking available behavioral and phar- of subjects who are highly motivated to quit and who macologic therapies can enhance successful quit rates are free of complicating diagnoses such as depression 2 by 2- to 3-fold over control conditions.
    [Show full text]
  • Neurocops: the Politics of Prohibition and the Future of Enforcing Social Policy from Inside the Body
    NEUROCOPS: THE POLITICS OF PROHIBITION AND THE FUTURE OF ENFORCING SOCIAL POLICY FROM INSIDE THE BODY RICHARD GLEN BOIRE1 I. INTRODUCTION .................................................................... 216 II. FROM DEMAND REDUCTION TO DESIRE REDUCTION.......................................................................... 216 III. PHARMACOTHERAPY DRUGS ............................................... 218 A. Target: Opiates............................................................ 218 B. Target: Cocaine........................................................... 221 C. Target: Marijuana....................................................... 222 D. Targeting Legal Drugs ................................................ 223 1. Target: Nicotine.................................................... 223 2. Target: Alcohol..................................................... 225 E. Pharmacotherapy Drugs: Good, Bad, Both, or Beyond?......................................................... 225 F. From Drug War to Drug Epidemic ............................. 230 IV. NEUROCOPS: LEGAL ISSUES RAISED BY COMPULSORY PHARMACOTHERAPY..................................... 234 A. Privacy and Liberty Interests Implicated by Involuntary Pharamacotherapy.............................. 234 B. Informed Consent......................................................... 236 C. At Risk Targets for Coercive Pharmacotherapy ........................................................ 238 1. Pharmacotherapy and Public Education.............................................................
    [Show full text]
  • Modulation of Immune Responses Using Adjuvants to Facilitate Therapeutic Vaccination
    Received: 6 March 2020 | Revised: 30 April 2020 | Accepted: 20 May 2020 DOI: 10.1111/imr.12889 INVITED REVIEW Modulation of immune responses using adjuvants to facilitate therapeutic vaccination Virgil Schijns1 | Alberto Fernández-Tejada2,3 | Žarko Barjaktarović4 | Ilias Bouzalas5 | Jens Brimnes6 | Sergey Chernysh7,† | Sveinbjorn Gizurarson8 | Ihsan Gursel9 | Žiga Jakopin10 | Maria Lawrenz11 | Cristina Nativi12 | Stephane Paul13 | Gabriel Kristian Pedersen14 | Camillo Rosano15 | Ane Ruiz-de-Angulo2 | Bram Slütter16 | Aneesh Thakur17 | Dennis Christensen14 | Ed C. Lavelle18 1Wageningen University, Cell Biology & Immunology and, ERC-The Netherlands, Schaijk, Landerd campus, The Netherlands 2Chemical Immunology Lab, Center for Cooperative Research in Biosciences, CIC bioGUNE, Biscay, Spain 3Ikerbasque, Basque Foundation for Science, Bilbao, Spain 4Agency for Medicines and Medical Devices of Montenegro, Podgorica, Montenegro 5Hellenic Agricultural Organization-DEMETER, Veterinary Research Institute, Thessaloniki, Greece 6Alk Abello, Copenhagen, Denmark 7Laboratory of Insect Biopharmacology and Immunology, Department of Entomology, Saint-Petersburg State University, Saint-Petersburg, Russia 8Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland 9Bilkent University, Ankara, Turkey 10Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia 11Vaccine Formulation Institute (CH), Geneva, Switzerland 12Department of Chemistry, University of Florence, Florence, Italy 13St Etienne University, St Etienne, France 14Statens
    [Show full text]
  • Update on Herpes Zoster: Treatment and Prevention of Shingles 27Th Annual Primary Health Care of Women Conference
    UPDATE ON HERPES ZOSTER: TREATMENT AND PREVENTION OF SHINGLES 27TH ANNUAL PRIMARY HEALTH CARE OF WOMEN CONFERENCE DECEMBER 5, 2019 PAMELA G. ROCKWELL, DO, FAAFP ASSOCIATE PROFESSOR DEPARTMENT OF FAMILY MEDICINE UNIVERSITY OF MICHIGAN NO FINANCIAL DISCLOSURES • AAFP Liaison of the Advisory Committee on Immunization Practices (ACIP) • AAFP Liaison ACIP Hepatitis, Pediatric and Adult RSV, and General Recommendations Work Groups • MAFP Liaison MDHHS Immunizations Committee • Co-Chair Immunization Committee, University of Michigan GOALS AND OBJECTIVES • Review Varicella Zoster Virus infection • Review Herpes Zoster (Shingles) Disease & Epidemiology • Review Shingles Risk Factors & Complications • Learn How to Diagnose and Treat Shingles and Common Complications • Learn How to Best Prevent Shingles/Update on Vaccination VARICELLA ZOSTER VIRUS (VZV) • Human α-herpesvirus, present worldwide, highly infectious • Primary infection with VZV causes varicella (chicken pox) • CDC estimate: ~ 4 million cases annually prior to 1995 • Annual incidence15-16 cases per 1,000 U.S. population • High annual burden of disease with hospitalization • 100-150 deaths per year https://www.cdc.gov/chickenpox/about/index.html CHICKENPOX • Transmitted person to person by direct contact, inhalation of aerosols from vesicular fluid of skin lesions of acute varicella or zoster (shingles), or aerosolized infected respiratory tract secretions CHICKENPOX • >95% of people born before 1980 in the U.S infected with wild-type VZV despite having no recall of disease* • VZV remains
    [Show full text]
  • Non-Live Recombinant Herpes Zoster Vaccine (SHINGRIX)
    Rx Files: Q&A Summary www.RxFiles.ca - Updated May 2021 Originally prepared by: M Jin, PharmD Non-Live Recombinant Herpes Zoster Vaccine (SHINGRIX) P L Bottom Line… SHINGRIX is indicated for the prevention of herpes zoster (HZ or shingles) in adults age ≥ 50 SHINGRIX reduces the risk of shingles by 91% (ARR=3.1%, NNT=32) & postherpetic neuralgia (PHN) by ~90% (ARR=0.30%, NNT=333) in 3 yrs. NNT: Eg. for every 333 vaccinated with SHINGRIX, 10 shingle cases (age ≥ 50 years) and 1 PHN cases (age ≥50 years) were prevented over ~ 3 yrs. SHINGRIX demonstrated efficacy for prevention of shingles effective in all age groups 50-80+. ZOSTAVAX less effective with increasing age. SHINGRIX use in patients with a history of shingles has been studied {open-label, non-randomized trial (n=93 patients, age 50-89 yr) for 3 months}.ZOSTER-033 Vaccine can be given after shingles symptoms/rash resolved CDC or ≥1 yr CDN Cost ~ $ 300 for 2 doses given intramuscularly (IM) 2-6 months apart (can give up to 12 months apart if needed to increase compliance). (Refrigerate 2 to 8°C; Discard if frozen) (New Jan/2021 NIHB covers for those between 65 & 70 years of age) Canadian NACI’18 recommends SHINGRIX should be offered to individuals ≥50 yrs without contraindications including: -Individuals previously vaccinated with ZOSTAVAX or ZOSTAVAX II; Re-vaccinate with two doses of RZV at least one year after receiving ZOSTAVAX -Individuals with a previous episode of herpes zoster disease. Provide two doses of SHINGRIX at least one year after herpes zoster episodeexpert opinion -Immunocompromised individuals, may be considered on a case-by-case assessment of the benefits vs risks expert opinion ZOSTAVAX II may be considered for immunocompetent individuals ≥50 yrs without contraindications when SHINGRIX is contraindicated, unavailable or inaccessible.
    [Show full text]
  • Gsk Vaccines in 2010
    GSK VACCINES IN 2010 Thomas Breuer, MD, MSc Senior Vice President Head of Global Vaccines Development GSK Biologicals Vaccines business characteristics Few global players and high barriers to entry – Complex manufacturing – Large scale investment Long product life cycles – Complex intellectual property High probability of R&D success – 70% post-POC New technology/novel products Better pricing for newer vaccines – HPV vaccines (Cervarix, Gardasil) – Pneumococcal vaccines (Synflorix, Prevnar-13) Operating margin comparable to pharmaceutical products Heightened awareness New markets 2 Research & development timelines Identify Produce Pre-Clinical Proof of Registration/ Phase I Phase II Phase III File Antigens Antigens Testing Concept Post Marketing Research (inc. Immunology) Pre-Clinical Development (inc. Formulation Science) Clinical Development (inc. Post Marketing Surveillance) Transfer Process to Manufacturing Build Facility x x Up to $10-20M Up to $50-100M $500M - $1B x x x 1-10 yrs 2-3 yrs 2-4 yrs > 1 yr GSK vaccines business 2009 sales £3.7 billion (+30%) +19% CAGR excl. H1N1 Vaccines represent 13% since 2005 of total GSK sales Sale s (£m) 4000 3500 Recent approvals: 3000 US: Cervarix 2500 EU: Synflorix 2000 Pandemic: Pandemrix; Arepanrix 1500 1000 500 0 2005 2006 2007 2008 2009 Increased Emerging Market presence Growth rate is CER 5 GSK vaccines: fastest growing part of GSK in 2009 2009 Sales Share Growth (CER) Respiratory £ 6,977m 25% +5% Consumer £ 4,654m 16% +7% Anti-virals £ 4,150m 15% +12% Vaccines £ 3,706m 13% +30% CV & Urogenital
    [Show full text]
  • View Board (KMUH-IRB-EXEMPT- We Further Investigated Whether HF Is a Time- 20130059)
    Wu et al. BMC Infectious Diseases (2015) 15:17 DOI 10.1186/s12879-015-0747-9 RESEARCH ARTICLE Open Access A nationwide population-based cohort study to identify the correlation between heart failure and the subsequent risk of herpes zoster Ping-Hsun Wu1,4, Yi-Ting Lin2, Chun-Yi Lin6, Ming-Yii Huang3, Wei-Chiao Chang5,7 and Wei-Pin Chang6* Abstract Background: The association between heart failure (HF) and herpes zoster has rarely been studied. We investigated the hypothesis that HF may increase the risk of herpes zoster in Taiwan using a nationwide Taiwanese population- based claims database. Method: Our study cohort consisted of patients who received a diagnosis of HF in 2001 ~ 2009 (N = 4785). For a comparison cohort, three age- and gender-matched control patients for every patient in the study cohort were selected using random sampling (N = 14,355). All subjects were tracked for 1 year from the date of cohort entry to identify whether or not they had developed herpes zoster. Cox proportional-hazard regressions were performed to evaluate 1-year herpes zoster-free survival rates. Results: The main finding of this study was that patients with HF seemed to be at an increased risk of developing herpes zoster. Of the total patients, 211 patients developed herpes zoster during the 1-year follow-up period, among whom 83 were HF patients and 128 were in the comparison cohort. The adjusted hazard ratio (AHR) of herpes zoster in patients with HF was higher (AHR: 2.07; 95% confidence interval (CI): 1.54 ~ 2.78; p < 0.001) than that of the controls during the 1-year follow-up.
    [Show full text]
  • Significant Items
    DEPARTMENT of HEALTH and HUMAN SERVICES FISCAL YEAR 2008 NATIONAL INSTITUTES OF HEALTH - Volume III Overview -- Significant Items Justification of Estimates for Appropriations Committees SIGNIFICANT ITEMS (SIs) FY 2007 House Appropriations Committee Report 109-515 and FY 2007 Senate Appropriations Committee Report 109-287 Table of Contents National Institutes of Health – Institutes and Centers National Cancer Institute (NCI) ...................................................................................... 1 National Heart, Lung, and Blood Institute (NHLBI)..................................................... 23 National Institute of Dental and Craniofacial Research (NIDCR) ................................. 41 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).............. 45 National Institute of Neurological Disorders and Stroke (NINDS)................................ 73 National Institute of Allergy and Infectious Diseases (NIAID) .................................. 101 National Institute of General Medical Sciences (NIGMS)............................................ 123 National Institute of Child Health and Human Development (NICHD) ....................... 127 National Eye Institute (NEI) ......................................................................................... 153 National Institute of Environmental Health Sciences (NIEHS) ..................................... 155 National Institute of Aging (NIA) ................................................................................. 163 National
    [Show full text]
  • High Aspect Ratio Viral Nanoparticles for Cancer Therapy
    HIGH ASPECT RATIO VIRAL NANOPARTICLES FOR CANCER THERAPY By Karin L. Lee Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Dissertation Advisor: Dr. Nicole F. Steinmetz Biomedical Engineering CASE WESTERN RESERVE UNIVERSITY August 2016 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Karin L. Lee candidate for the Doctor of Philosophy degree*. (signed) Horst von Recum (chair of the committee) Nicole Steinmetz Ruth Keri David Schiraldi (date) June 29, 2016 *We also certify that written approval has been obtained for any proprietary material contained therein. TABLE OF CONTENTS Table of Contents List of Tables .................................................................................................................... ix List of Figures and Schemes .............................................................................................x Acknowledgements ........................................................................................................ xiv List of Abbreviations .................................................................................................... xvii Abstract......................................................................................................................... xxiii Chapter 1: Introduction ....................................................................................................1 1.1 Cancer statistics...............................................................................................................1
    [Show full text]
  • Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
    Morbidity and Mortality Weekly Report Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines Kathleen L. Dooling, MD1; Angela Guo, MPH1; Manisha Patel, MD1; Grace M. Lee, MD2; Kelly Moore, MD3; Edward A. Belongia, MD4; Rafael Harpaz, MD1 Introduction Methods On October 20, 2017, Zoster Vaccine Recombinant, From March 2015 to October 2017, the ACIP Herpes Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Zoster Vaccines Work Group (Work Group; see acknowl- Triangle Park, North Carolina), a 2-dose, subunit vaccine edgments for members and their affiliations) participated containing recombinant glycoprotein E in combination with in monthly or bimonthly teleconferences to review herpes a novel adjuvant (AS01B), was approved by the Food and zoster epidemiology and the evidence for the efficacy, safety, Drug Administration for the prevention of herpes zoster in and programmatic factors of RZV and ZVL. According to adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL the Grading of Recommendations Assessment, Development each), administered intramuscularly, 2–6 months apart (1). On and Evaluation (GRADE) approach, the Work Group defined October 25, 2017, the Advisory Committee on Immunization critical and important outcomes, conducted a systematic Practices (ACIP) recommended the recombinant zoster vaccine review of the evidence, and subsequently reviewed and dis- (RZV) for use in immunocompetent adults aged ≥50 years. cussed findings and evidence quality (https://www.cdc.gov/ Herpes zoster is a localized, usually painful, cutaneous erup- vaccines/acip/recs/grade/) (9). tion resulting from reactivation of latent varicella zoster virus A cost effectiveness analysis comparing RZV, ZVL, or no (VZV).
    [Show full text]
  • Communicable Disease (CD) Quarterly Report San Francisco Department of Public Health 2018 Quarter 2 • November 26, 2018
    Communicable Disease (CD) Quarterly Report San Francisco Department of Public Health 2018 Quarter 2 • November 26, 2018 Disease Reporting: 415-554-2830 (phone); 415-554-2848 (fax); http://www.sfcdcp.org Tomás Aragón, MD, DrPH, Health Officer Juliet Stoltey, MD, MPH, Director, Communicable Disease Control and Prevention The Communicable Disease Control Unit receives and responds to reports of communicable diseases. For urgent reports during business hours, please call (415) 554-2830. For urgent or emergent reports after hours, please call (415) 554-2830 and follow instructions to contact the on-call physician. For non-urgent reports, please fax a Confidential Morbidity Report (CMR) to (415) 554-2848. Please see our website for more information: http://www.sfcdcp.org Sign up to receive Health Alerts at: https://www.sfcdcp.org/health-alerts-emergencies/health-alerts/register-for-health-alerts/ Table 1: Number of Selected Reported Communicable Disease Cases Current Recommendations for Shingles Prevention 2018 2017 Herpes zoster, or shingles, is a painful vesicular rash caused by reactivation of Q2 Q1-Q2 Q2 Q1-Q2 the varicella-zoster virus (VZV, the virus that causes chickenpox). The rash most commonly occurs in a dermatomal distribution and usually heals in 2-4 weeks. Botulism 0 0 1 1 In 10-13% of cases over age 50, a painful postherpetic neuralgia develops that Invasive Meningococcal Disease 0 0 0 0 may last for weeks, months, and occasionally, years. Risk of shingles increases # with age; CDC estimates a 50% lifetime risk in persons living to age 85. Altered Meningitis— Bacterial 1 4 4 6 immunocompetence increases the risk for shingles as well as risk of severe Meningitis— Viral 7 9 2 4 complications.
    [Show full text]